Bristol-Myers Squibb's Iza-Bren Achieves Dual Survival Endpoints in Breast Cancer Trial
Bristol Myers Squibb and SystImmune reported that antibody-drug conjugate izalontamab brengitecan achieved statistically significant improvements in both progression-free and overall survival versus chemotherapy in a Phase III trial for triple-negative breast cancer.
In late February 2026, Bristol Myers Squibb and partner SystImmune reported that antibody-drug conjugate izalontamab brengitecan (iza-bren) achieved statistically significant, clinically meaningful improvements in both progression-free and overall survival versus chemotherapy in a Phase III trial for previously treated unresectable locally advanced or metastatic triple-negative breast cancer. This marks the third successful pivotal study for iza-bren and the first bispecific antibody-drug conjugate to report dual positive survival endpoints in a Phase III triple-negative breast cancer setting.
The Phase III survival win in triple-negative breast cancer strengthens the case that newer oncology assets can help offset looming patent cliffs on Eliquis and Opdivo while funding a sizable dividend and debt load. The most important near-term catalyst remains regulatory and commercial execution across multiple filings.
Among recent announcements, the FDA's priority review for iberdomide in relapsed or refractory multiple myeloma looks especially relevant. Alongside iza-bren, it highlights how Bristol Myers is leaning on next-generation oncology modalities, from CELMoD agents to antibody-drug conjugates, to broaden its cancer franchise. How quickly drugs like iberdomide can move from approval into meaningful real-world use will be central to whether these pipeline wins translate into catalysts that matter for shareholders over the next few years.
Bristol-Myers Squibb's narrative projects $41.3 billion revenue and $9.2 billion earnings by 2028. This implies a 4.7% yearly revenue decline but a $4.2 billion earnings increase from $5.0 billion today.